05:15 PM EST, 11/03/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

HOLX delivered Q4 revenue of $1,049.5M (+6.2% Y/Y) and diluted EPS of $1.13 (+11.9% Y/Y), demonstrating solid performance across key business segments. Diagnostics posted $454.1M revenue (+2.4% Y/Y) with 5.4% organic growth ex-Covid, while Covid-19 revenue declined 27.3% Y/Y as expected, and Breast Health revenue of $393.7M grew 4.8% Y/Y reflecting continued U.S. sales execution improvements. Skeletal Health showed remarkable recovery with revenue surging 129.9% Y/Y to $29.2M, successfully resolving prior DXA manufacturing constraints that had hampered performance. The company did not provide guidance considering the pending buyout transaction. Non-GAAP operating margin expanded 120 bps Y/Y to 31.2% due to operating leverage, though gross margin declined 60 bps to 60.9% from product mix shifts and increased tariff expenses. We see no reason for the company not to be acquired at the previously announced $79/share buyout.